Menu Search
Equities

Prophase Labs Inc

PRPH:NAQ

Prophase Labs Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.7736
  • Today's Change-0.003 / -0.42%
  • Shares traded134.03k
  • 1 Year change-82.62%
  • Beta-0.2576
Data delayed at least 15 minutes, as of Nov 22 2024 16:06 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Prophase Labs Inc's revenues fell -63.81% from 122.65m to 44.38m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 18.46m to a loss of 16.78m.
Gross margin-32.38%
Net profit margin-217.64%
Operating margin-277.69%
Return on assets-30.25%
Return on equity-58.71%
Return on investment-40.11%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Prophase Labs Inc fell by 6.96m. Cash Flow from Financing totalled 5.76m or 12.97% of revenues. In addition the company used 11.35m for operations while cash used for investing totalled 1.37m.
Cash flow per share-1.09
Price/Cash flow per share--
Book value per share2.00
Tangible book value per share1.18
More ▼

Balance sheet in USDView more

Prophase Labs Inc has a Debt to Total Capital ratio of 28.37%, a higher figure than the previous year's 7.86%.
Current ratio1.47
Quick ratio1.33
Total debt/total equity0.3961
Total debt/total capital0.2837
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.